Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors

This publication has 32 references indexed in Scilit:

• Identification of p21 as a Direct Target of EWS-Fli1 Oncogenic Fusion Protein
  Published by Elsevier ,2003
• Histone deacetylase inhibitors: from target to clinical trials
  Expert Opinion on Investigational Drugs, 2002
• Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues
  Japanese Journal of Cancer Research, 2001
• Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G1regulatory genes
  British Journal of Cancer, 2001
• Apoptotic Cytotoxic Effects of a Histone Deacetylase Inhibitor, FK228, on Malignant Lymphoid Cells
  Japanese Journal of Cancer Research, 2000
• Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia
  Nature, 1998
• EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.
  Journal of Clinical Investigation, 1997
• EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations.
  Journal of Clinical Investigation, 1994
• FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
  The Journal of Antibiotics, 1994
• Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.
  Proceedings of the National Academy of Sciences, 1993